The use of colony stimulating factors and collection of PBPC from allogeneic donors has been introduced into clinical practice as a safer alternative to bone marrow harvest. We report a case where a donor suffered a fatal stroke following filgrastim administration. A 73-year-old man was identified as a genotypic HLA match with his 57 year old brother, a patient with Chronic Myeloid Leukaemia. He had a long-standing history of hypertension and angina. Because of cardiovascular problems he was felt, after independent review to be unfit for GA but suitable for PBPC mobilisation and collection. He received filgrastim 10 g/kg daily × 6 and underwent 3 PBPC collections on COBE Spectra. The peak WBC was 43.5 × 10 9 /l. Apart from bone pain no adverse events occurred during the collection period. Several days after the procedure his family noted a deterioration in intellectual performance and mobility. This was followed by a dense right side stroke from which he died 2 weeks later. Diffuse cerebral haemorrhage is the reported dose limiting toxicity for filgrastim in primates, and raised G-CSF levels have been reported following strokes in man. We conclude that PBPC collection may not be safer than marrow harvest, and that donors who are high risk for GA may also be at risk from PBPC mobilisation.
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